Collagen + Mānuka honey like never before.

We understand the heavy burden non-healing wounds can have on you and your loved ones' daily life.

Let’s take the next step together. At SweetBio®, we’ve made it our mission to simplify your journey to closure with our new easy-to-apply VERIS™ + APIS® wound dressings.

The SweetBio® Difference

  • With a barely-there feel, our products work fast, are easy to use, and leverage the known wound care benefits of Manuka honey without the mess.

  • Our products are clinically proven to reduce time to wound closure [1,2] compared to well-documented standards of care.

    [1] Rodriguez et al. 2020

    [2] McMurray et al. 2020

  • Covered by Medicare, our products meet you where you are.

Our Products

VERIS™

VERIS™ is is the first advanced wound care product to deliver on performance, ease, and affordability for the millions recovering from Mohs surgery, biopsies, and chronic ulcers. 

APIS®

APIS® is a bioengineered wound product for the management of chronic and acute wounds that covers and protects wounds, absorbs exudate, and creates a moist wound environment.

Backed by Evidence

  • Clinical Publication: 37 Patient Mohs Dermatologic Surgery RCT

    Published in Dermatologic Surgery, this randomized controlled trial (RCT) conducted by the Dermatology Department at Vanderbilt University Medical Center compared SweetBio®’s technology and secondary intention healing (SIH) to support wound closure post-Mohs. Results demonstrated improved wound healing with SweetBio®’s technology showing significant reduction in pain scores and favorable skin thickness.

    Download

  • Clinical Publication: 12 Patient Lower Extremity Chronic Wound Case Series

    Published in The International Journal of Lower Extremity Wounds, this clinical evaluation involved 5 physicians across 4 states using SweetBio®’s technology to treat non-healing chronic ulcers. Patients achieved 100% closure within 8 weeks, with a mean closure time of 4.1 weeks.

    Download

  • Clinical Publication: 8 Patient Mohs Dermatologic Surgery Case Series

    Published in Dermatologic Surgery, this clinical evaluation conducted by the Dermatology Department at Vanderbilt University Medical Center used SweetBio®’s technology to support wound closure post Mohs (skin cancer removal) surgery. Results demonstrated complete re-epithelialization was achieved within an average of 6 weeks.

    Download

  • Clinical Publication: 43 Patient Chronic Wound Healing in an Urban Hospital Wound Clinic

    Published in Wounds, this retrospective IRB-approved clinical evaluation assessed chronic wound closure rates using standard of care (SOC) or treatment with SweetBio®’s technology in an urban hospital wound clinic. In both groups, most wounds did not close for several reasons, mainly patient compliance. For wounds that did close, the average time to closure was two times faster for SweetBio®’s technology compared to SOC (7.4 weeks and 14.8 weeks, respectively; p < .05).

    Download

  • In Vitro Publication: Bacteria Reduction

    Published in Biomedical & Translational Science, this data demonstrates SweetBio®’s technology ability to significantly reduce both Staphylococcus Aureus and Pseudomonas Aeruginosa by 99.99% compared to a non-treated surface after 24 hours, in vitro.

    Download

  • In Vitro Publication: Controlling Inflammation and Growth Factors

    Published in the International Journal of Biomaterials, this data demonstrates SweetBio®’s technology ability to significantly decrease (to negligible levels) the expression of MMP-9 from macrophages and trigger the release of pro-regenerative growth factors from fibroblasts such as FGFb and VEGF, in vitro.

    Download

  • In Vitro Publication: Direct Comparison of Collagen Dressing vs. Manuka Honey Dressing vs. SweetBio®’s Technology

    Published in the International Journal of Molecular Sciences, this data highlights the superior comprehensive approach that SweetBio®’s technology has over collagen dressings and Manuka honey dressings, specifically comparing MMP-9/TIMP-1 ratios and pro-regenerative growth factor secretion, in vitro.

    Download